IDH1 and central nervous system cancer: FGFR3::TACC3 fusion has been identified in approximately 4% of diffuse gliomas, IDH-wildtype, highlighting the distinct molecular and pathological characteristics that distinguish it from other glioma subtypes [2,[5], [6], [7], [8], [9], [10]].